Alnylam reports updated positive interim phase 1 results for aln-app, in development for alzheimer's disease and cerebral amyloid angiopathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny) announced today updated positive interim results for the ongoing single ascending dose portion of the phase 1 study of aln-app, an investigational rnai therapeutic targeting amyloid precursor protein (app) in development for the treatment of alzheimer's disease and cerebral amyloid angiopathy (caa). the results were presented at the 2023 alzheimer's association international conference (aaic) being held july 16-20,.
ALNY Ratings Summary
ALNY Quant Ranking